Terns raises $87M to advance trials of NASH drugs
The startup, which licensed three NASH candidates from Eli Lilly, raised $87 million from the drugmaker and Deerfield Management.
Lilly seeks emergency clearance for Covid-19 monoclonal antibodies on Phase II data
The company announced data on the combination of two antibodies against the SARS-CoV-2 virus, showing significant reductions in viral load compared with placebo. The company has applied for an EUA for LY-CoV555 and will seek an authorization for the combination of that drug with LY-CoV016 next month.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Combo study of Gilead antiviral, Lilly anti-inflammatory drug positive in Covid-19, but raises pricing jitters
An analyst wrote Wednesday that the combination of Lilly's Olumiant and Gilead's Veklury, or remdesivir, could cost nearly $8,000, a high price tag that could potentially hamper uptake, especially given the availability of cheaper drugs like dexamethasone.
Lilly’s Covid-19 antibody reduced viral load faster than placebo, interim Phase II data show
The company said that patients receiving LY-CoV555 at the 2,800mg dose showed a lower rate of hospitalization and emergency room visits than those on placebo. However, the other dose levels of the drug did not reach the viral load primary endpoint. An analyst called the data "mixed but constructive."
Lilly launches Phase III study of arthritis drug in Covid-19
The company said it had initiated the Phase III study of Olumiant, one of multiple JAK inhibitors that are being tested to find if they can mitigate the cytokine storm associated with Covid-19's worst complications.
Blueprint gets FDA priority review for competitor to newly approved Lilly cancer drug
Phase I/II data for pralsetinib in non-small cell lung cancer are the subject of a poster presented at the ASCO meeting. An expert noted the similarity between its clinical activity and that of Lilly's drug, Retevmo. Both are RET inhibitors.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
With new lung cancer data at ASCO, Blueprint Medicines nips at Eli Lilly’s heels
The company will present a poster on pralsetinib, its RET inhibitor, which some analysts wrote they view as being "interchangeable" with Lilly's Retevmo, which received accelerated FDA approval last week.
Lilly drug for cancers with highly targetable genetic abnormality gets FDA nod
The agency granted accelerated approval to Retevmo in RET fusion-positive non-small-cell lung cancer and thyroid cancer and RET-mutated medullary thyroid cancer. The company is mounting a virtual rollout effort as sales staff are grounded due to the Covid-19 pandemic, an exec said.
Here’s how some big U.S. drugmakers expect Covid-19 to affect them this year
Several companies have adjusted their earnings-per-share forecasts for the year from what they had issued when they announced fourth-quarter 2019 earnings or expect to see negative impacts on sales of certain drug products, while others reaffirmed guidances.
Lilly arthritis pill to be included in NIAID’s Phase III Covid-19 trial of multiple drugs
The Adaptive Covid-19 Treatment Trial will include several investigational therapies for Covid-19, including Lilly's Olumiant, investigated for efficacy against inflammation caused by the disease.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
As Covid-19 hinders clinical trial operations, research staff are finding themselves out of work
A recruiter in the industry said trial-monitoring staff report having their hours cut, while CRAs are grounded, and others have reported being laid off on social media. Several drugmakers have wound down clinical trial operations as the pandemic has overwhelmed a growing number of hospitals.
Lilly delays new clinical trials, enrollments as Covid-19 bogs down study sites
The drugmaker said it would delay new study starts and also enrollments in ongoing studies due to the strain the pandemic is putting on clinical trial sites. However, patients already enrolled in trials can continue treatment. Bristol-Myers Squibb said it would continue to assess trial operations.
Amid high insulin prices, many patients turn to unregulated sales on Craigslist, study shows
While many sellers were found to express altruistic motives, the researchers wrote that improperly stored insulin creates risks of lost potency and contamination. The findings highlight the need for substantive policy reform, according to the study's lead author.
Another blow to Alzheimer’s field as two drugs fail in study of early-onset disease
Lilly and Roche said that the Phase II/III DIAN-TU trial of their amyloid beta-targeting drugs - gantenerumab and solanezumab - failed to meet its primary endpoint in patients genetically predisposed to early-onset Alzheimer's disease.
Eli Lilly acquires skin disease-focused Dermira in $1.1B deal
The California-based dermatology company's lead product candidate is a Phase III monoclonal antibody being developed for a type of eczema. Another company, Denmark-based LEO Pharma, has a Phase III drug in the same class for the same disease.